Navigation Links
Shire Announces Positive Results of Studies With Guanfacine,Extended Release, An Investigational Nonstimulant Medication Filed,for the Treatment of ADHD in Children and Adolescents

nts With Attention-Deficit/Hyperactivity Disorder (Trial 303)

J. Biederman, M.D.; R. Melmed, M.D.; Anir Patel, M.D.; Keith McBurnett, M.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

APA Poster # NR657

Wednesday, May 23, 2007 at 12 p.m. PDT (3 p.m. EDT)

Interim Results of a Long-Term, Open-Label Study of Guanfacine Extended Release in Children and Adolescents Aged 6 to 17 Years With Attention- Deficit/Hyperactivity Disorder (Trial 305)

F. Sallee, M.D.; J. Biederman, M.D.; J. McGough, M.D.; T. Wigal, Ph.D.; J. Donahue, M.P.H.; A. Lyne, M.S.C.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on ADHD, human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire's focused strategy is to develop and market products for specialty physicians. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company's website: www.shire.com

THE "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

Statements included herein that are not historical facts are forward- looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire's results could be materially affected. The risks and uncertainties inclu
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
(Date:7/29/2014)... SAN DIEGO , July 29, 2014 Pfenex ... its previously announced initial public offering of 8,333,333 shares of ... $6.00 per share. All of the common stock was offered ... 30-day option to purchase up to 1,250,000 additional shares of ... of common stock are traded on the NYSE MKT under ...
(Date:7/29/2014)... 2014 Edwards Lifesciences Corporation (NYSE: EW ... and hemodynamic monitoring, today reported net income for the quarter ... diluted share, and non-GAAP net income of $94.0 million, or ... a year earlier was $93.3 million, or $0.81 per diluted ... per diluted share.  Net sales for the ...
(Date:7/29/2014)... ALBANY, New York , July 29, 2014 /PRNewswire/ ... published by Transparency Market Research "Surgical Navigation Systems Market ... Systems) - Global Industry Analysis, Size, Share, Growth, Trends ... systems market was valued at USD 218.5 million in ... of 4.5% from 2014 to 2020, to reach an ...
Breaking Medicine Technology:Pfenex Announces Closing of Initial Public Offering 2Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19Edwards Lifesciences Reports Strong Second Quarter Results 20Edwards Lifesciences Reports Strong Second Quarter Results 21Edwards Lifesciences Reports Strong Second Quarter Results 22Edwards Lifesciences Reports Strong Second Quarter Results 23Edwards Lifesciences Reports Strong Second Quarter Results 24Edwards Lifesciences Reports Strong Second Quarter Results 25Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 2Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 3Surgical Navigation Systems Market Expected to Reach USD 295.5 Million Globally in 2020: Transparency Market Research 4
... Pa., April 14 Consumers who,purchased raw milk ... after March 18 should discard it immediately due ... Dennis Wolff,said today., Raw milk is milk ... selling raw milk must be permitted and have ...
... cisplatin observed in ovarian carcinoma xenografts, DUBLIN, ... ), a pharmaceutical company dedicated to the discovery, ... and,hematological malignancies, today announced as part of a ... that S-110, its DNA,methyltransferase inhibitor, improves in vivo ...
Cached Medicine Technology:SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine 2SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine 3
(Date:7/30/2014)... July 30, 2014 Pain Free Living ... sports bracelet for pain relief and improved performance. This ... titanium embedded in a silicone core that is sheathed ... Germanium and is embedded with scalar energy and Schumann ... “Pain Free Living has 12 years experience developing magnetic ...
(Date:7/29/2014)... 30, 2014 Recently, iFitDress.com, a well-known wedding ... satin bridal gowns . Aside from this, it has ... up to 68 percent off. All of its old and ... The company’s sales representative says excitedly, “We are pleased to ... new range, there are a lot of amazing items. It ...
(Date:7/29/2014)... a well-known online supplier, now allows worldwide clients to ... by providing graceful and sexy lingerie collection for August. ... sexy dresses , designed and developed by top ... price into consideration. Worry no more, because VogueQueen.com launches ... for all clients. , VogueQueen.com’s top designers sincerely ...
(Date:7/29/2014)... 2014)A diet rich in soy may help feminine hearts, ... today in Menopause , the journal of The ... to the diet of women in Asia, produces the ... similar to Asian migrants to North America, leads to ... and switching to soy from a Western diet after ...
(Date:7/29/2014)... Daily Gossip indicates in its Natural Cure ... for any sufferer who is looking for an all-natural holistic ... the new program, Sarah Summer, says that her method is ... infection, too. Actually, this is the reason why she was ... , The Natural Cure for Yeast Infection review ...
Breaking Medicine News(10 mins):Health News:Superior Magnetics Released New Magnetic Sports Bracelet for Pain 2Health News:Cheap Satin Bridal Gowns Recently Provided By Well-known Supplier iFitDress.com 2Health News:VogueQueen.com Now Provides Graceful And Sexy Lingerie Collection For August 2Health News:Soy may help women's hearts if they start early 2Health News:Natural Cure for Yeast Infection Review Reveals Sarah Summer’s Healing Method 2
... Cause of Death in Long-Term Survivors of Hereditary Retinoblastoma ... increased risk of death due to a second cancer, ... a very rare cancer of the eye that affects ... of retinoblastoma are at risk of subsequent malignancies but ...
... Hear Public Comments on Comparative Effectiveness Research ... 7 The Federal Coordinating Council for ... listening session on April 14, 2009, in ... comment regarding comparative effectiveness research and the ...
... to worse outcomes , , TUESDAY, April 7 (HealthDay News) ... more likely to die or need a second heart ... according to the results of a U.S. study. , ... who received their first heart transplant at Children,s Hospital ...
... but activity is safe and should be urged, expert says, ... of moderate exercise will not harm people with heart failure ... has found. , That admittedly tepid conclusion comes from a ... at 82 centers in the United States, Canada and France. ...
... Mayo Clinic researchers have discovered the mechanisms behind two ... that may ultimately allow investigators to benchmark progression of ... findings appear in the current online issue of ... by Edward Leof, Ph.D. , Mayo Clinic biochemist, ...
... of Global Breast Cancer Movement Continues Unprecedented Investment ... Committed to caring for those coping with ... of the disease, Susan G. Komen for the ... announced $60 million in research grants to U.S. ...
Cached Medicine News:Health News:Also in the April 7 JNCI 2Health News:Also in the April 7 JNCI 3Health News:Also in the April 7 JNCI 4Health News:Federal Coordinating Council on Comparative Effectiveness Research to Hold Public Listening Session in Washington, DC 2Health News:Heart Transplant Failures More Likely in Poor, Minority Kids 2Health News:Exercise Might Benefit Some With Heart Failure 2Health News:Exercise Might Benefit Some With Heart Failure 3Health News:Mayo researchers discover mechanism of cell type-specific signaling in tumor development 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 2Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 3Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 4Health News:Susan G. Komen For The Cure(R) to Invest $60 Million in Research to Accelerate Breast Cancer Cures, Eliminate Disparities, Improve Diagnoses 5
... continuous low-flow nebulizer performance. Patented auxiliary ... allows for optimal medication and Heliox ... OMNI~NEB takes on severe asthma, COPD ... critical care situations. Configure with a ...
... metered dose inhalers., ,ACE ensures prompt, ... canisters. Its versatile design allows it to ... conjunction with an endotracheal airway or resuscitation ... may also be used in conjunction with ...
... Mouthpiece 7FT O 2 Tubing Tee Adapter ... are designed to provide maximum aerosol quality and ... fast treatment time. Each of these high-efficiency nebulizers ... vent seal adapter for use with your ventilator ...
Nebulizer Custom Kit...
Medicine Products: